secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2026-09-23T20:05:21+00:00
Accession:  0001493152-26-043919
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem signs manufacturing deal with Zhaoke for PHEXX, targets 40%+ cost cut
----------------------------------------------------------------------------

- Manufacturing agreement with Zhaoke (Hong Kong) and Zhaoke (Guangzhou) dated Sept 17, 2026.
- Expected to reduce PHEXX unit costs by 40% or more after FDA approval, improving economics.
- Plans sNDA submission to FDA in mid-2027 for PHEXX from the new facility.
- Adds second supply source to boost flexibility and capacity for US and global growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226043919/0001493152-26-043919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226043919/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-043919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer